

(free) CME-certified* Dinner Symposium

Arresting MASLD/MASH-Related Fibrosis Progression & Sequelae in PwD T2

AACE 2025 Annual Meeting

Approved for 2.0 AMA PRA Category 1 Credit(s)[™]

Wednesday
May 14, 2025

6:30 pm Registration/Dinner
7:00 - 9:00 pm Program

Hilton Orlando
Room: Florida 5-7



Forward this
Program Guide
cgmEDUCATION.net/guide



Chairperson

Zobair M. Younossi

MD, MPH, FACP, FACG,
AGAF, FAASLD



Christina Hanson

MS, FNP



Diana Isaacs

PharmD, BCPS, BCACP, CDCES,
BC-ADM, FADCES, FCCP



Marcelo Kugelmas

MD, FAASLD, FACP

cgm EDUCATION.net[™]
Consortium for Integrated Diabetes Device Education

>40,000 Members *and growing*

Multi-Award Winning
Medical Education



Provided by **c m i** CogniMed inc **TMA** Translational Medicine Association

Information provided in this presentation is not endorsed by AACE.
This activity is supported by an independent educational grant provided by **Madrigal Pharmaceuticals**.

*Pharmacists, Nurses and Allied-health Professionals may claim AMA credit based on State acceptance.

INTENDED AUDIENCE

Diabetologists, Endocrinologists, Certified Diabetes Care and Education Specialists, Hepatologists, Cardiologists, Primary Care Physicians, Physician Assistants, Nurse Practitioners, Pharmacists and other Health Care Professionals interested in the management of diabetes and liver disease.

EDUCATIONAL OBJECTIVES

After participating in this program, learners will be better able to:

1. Recognize how Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD/NAFLD) covers a broad spectrum of histological conditions, which increase both hepatic and non-hepatic morbidity/mortality, and how it can advance Metabolic-associated Steatohepatitis to (MASH/NASH).
2. Assess MASLD comorbidities and pathogenic drivers, including type 2 diabetes.
3. Develop MASLD/MASH diagnostic strategies.
4. Identify existing available management protocols as well as novel treatment modalities to mitigate the burden of MASLD/MASH and optimize patient outcomes and QoL.

ACCREDITATION AND DESIGNATION

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Tennessee Medical Association and CogniMed Inc. The Tennessee Medical Association is accredited by the ACCME to provide continuing medical education for physicians.

The Tennessee Medical Association designates this other activity (live, in-person, then on-demand) for a maximum of **2.0 AMA PRA Category 1 Credits™**. Physicians should claim only the credit* commensurate with the extent of their participation in the activity. (release date: May 14, 2025; expiration date: May 14, 2026).

*Pharmacists, Nurses and Allied-health Professionals may claim AMA credit based on State acceptance.

DISCLOSURE POLICY

ACCME guidelines require that anyone who is in a position to develop or contribute to the development of the content must disclose to the participants in a continuing education activity any relevant financial relationships with any proprietary entity that produces, markets to, re-sells or distributes healthcare good or services used on or to patients. If financial relationships are present, ACCME guidelines require that an individual who has the financial relationships demonstrate that the information used in the role(s) identified above is based on the educational needs of physicians, rigorous scientific evidence

from research or the clinical experience of experts and was developed independently of commercial influences.

Within the past 12 months:

Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF, FAASLD has had financial interest or affiliation with the following companies: Research funding and/or consultant/advisor for Intercept, Cymabay, Boehringer Ingelheim, Ipsen, BMS, GSK, NovoNordisk, Siemens, Madrigal, Merck, Aligos, Akero, Sanofi, Abbott.

Marcelo Kugelmas, MD, FAASLD, FACP has had financial interest or affiliation with the following companies: Consultant for Madrigal, Novo Nordisk. Research for Madrigal. Speaker for Madrigal, Novo Nordisk

Christina Hanson, MS, FNP has had financial interest or affiliation with the following companies: Speaker for Madrigal, Novo Nordisk

Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP has had financial interest or affiliation with the following companies: Consultant for Sanofi, Medtronic, Sequel. Speaker for Dexcom, Abbott, Insulet, Novo Nordisk, Lilly, Medtronic

Editorial:

CogniMed staff and planners have no financial interest or affiliation to disclose.

Commercial Support:

Madrigal Pharmaceuticals (Grant)

Disclaimer:

This content and views presented in this educational activity are those of the authors and do not necessarily reflect those of CogniMed Inc., or Madrigal Pharmaceuticals. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject

This activity is supported by an independent educational grant provided by **Madrigal Pharmaceuticals**.

Jointly provided by



Claim CME* Credit

Please complete the Posttest/Evaluation
at cgmEDUCATION.net/aace

*Pharmacists, Nurses and Allied-health Professionals may claim AMA credit based on State acceptance.

QueRY

Questions R Yours
cgmeducation.net/query



Go to cgmEDUCATION.net/query
- or -
cgmEDUCATION.net home page
click the QueRY banner (mobile or desktop)


- Ask Questions to the Faculty
- Refer a Colleague
- Get CME*
- Download Materials/Slides

*Pharmacists, Nurses and Allied-health Professionals may claim AMA credit based on State acceptance.

You might also like...

(free) .75 hour CME-certified*

**MASLD/MASH
in People with Diabetes:
'24 Guidelines on Identification
Diagnosis · Management with Novel Therapies**
with Carol Wysham, MD



Great, thought-provoking presentation!

*Pharmacists, Nurses and Allied-health Professionals may claim AMA credit based on State acceptance


from the American Diabetes Association's
83rd Scientific Sessions

**Managing NAFLD/NASH
in People with T2 Diabetes:
Disease Burden · Diagnosis ·
Current & Emerging Armamentarium**




cgmEDUCATION.net
Consortium for Glucose Management

*Perhaps the BEST lecture
I have attended in 35+
years of practice*




Type 2 Diabetes and NAFLD are Mutually Detrimental



**NAFLD/NASH in PwD:
Guidelines on Identification
Diagnosis · Management
w/Current & Future Modalities**
Scott Isaacs, MD, FACE, FACP

*These on-line education
sessions are VERY
valuable!*

Go to www.cgmEDUCATION.net




Chairman
Global NASH Council
Washington, DC
Professor and Chairman
Beatty Liver and Obesity
Research
Inova Health System
Falls Church, Virginia


Global Epidemiology of MASLD/MASH: Understanding the Impact... Addressing the Urgency

Clinical Care Decision Making: AACE & other Guidelines for Management of MASLD/MASH in PwD T2


Zobair M. Younossi, MD, MPH is the Chairman of the Global NASH Council, Washington DC and Professor and Chairman of Beatty Liver and Obesity Research, Inova Health System, Falls Church, Virginia. Dr Younossi earned his medical degree from University of Rochester (AOA 1989) with fellowship training in at Scripps Clinic and Research Foundation (1989-1995), while earning his Master of Public Health with multiple honours from San Diego State University (1995). He then worked at Cleveland Clinic Foundation before establishing the Beatty Liver and Obesity Research program and Inova Liver Center. He has served as the Chairman of Department



of Medicine, Inova Fairfax (2011-2024), President of Inova Medicine (2019-2024), Chairman of Research for Inova (2005-2022) and Vice Chairman of the Board of Inova Foundation (2011-2024). He currently serves as President of Chronic Liver Disease Foundation (2018-Present). Dr Younossi has pioneered research in MASLD/NAFLD and outcomes research in Liver Disease and has authored over 770 articles.



1090 abstracts and 510 faculty lectures in national and international meetings. He has an H-index of 117 and is listed as the most cited scholars in Liver Disease and NAFLD according to Scholar GPS-2022. Dr Younossi has served on the editorial board of several journals, including Co-Editor of Liver International and Associate Editor of J Hepatology.






Marcelo Kugelmas
MD, FAASLD, FACP

South Denver
Gastroenterology
Englewood, Colorado


Novel Therapies to Arrest/Reverse Fibrosis Burden of MASLD/MASH: Flattening the Curve with Durable Response

October 2024 updates to AASLD Practice Guidance: Patient Selection



Dr Marcelo Kugelmas received his medical degree with honors from the University of Buenos Aires. After completing his internship and internal medicine residency at University of Southern California-Los Angeles County Hospital in Los Angeles, he moved to Cleveland where he completed his gastroenterology fellowship at the Cleveland Clinic Foundation, and served as Chief Fellow in 1994 -1995. He then moved to Lexington, Kentucky where he pursued further training in hepatology, liver transplantation and

Assessment for Treatment Outcomes in Patients Receiving Resmetirom




advanced endoscopy. Dr Kugelmas remained there until 2000 as an assistant professor. He then moved to Colorado, where he joined the University of Colorado Liver section.

Over the last 20 years Dr Kugelmas' main focus has been on the care of patients with liver diseases. He became an associate professor of medicine in 2004, before joining South Denver Gastroenterology. Dr Kugelmas is a national lecturer on topics of chronic liver disease, has presented regularly at multiple gastroenterology, liver and transplantation annual meetings, and has published more than 40 papers in peer-reviewed journals.

Resmetirom: the Only FDA approved Medication for the Treatment of MASH

- Resmetirom is a thyroid hormone receptor (THR)- β selective agonist designed to target key underlying causes of NASH in the liver.
- The FDA has approved resmetirom for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).




Azam M et al. Explor Drug Sci. 2024;2:867-874. Brennan, PM. nrgj Gut Liver 2, 3 (2025).



Christina Hanson
MS, FNP

South Denver
Gastroenterology, P.C
Englewood, Colorado

Partnership in MASLD/MASH Management: A Multidisciplinary Approach




Christina Hanson is a certified family nurse practitioner and has been working at South Denver Gastroenterology in Denver Colorado for nearly 18 years as an advanced practice provider. She received her Bachelors of Science in Nursing at Bethel University in St. Paul, MN. In 2005, she returned to school and obtained her MSN after completing the Family Nurse Practitioner program at Regis University. Christina is a course director and board of trustee for GHAPP and an active researcher with extensive leadership and teaching

experience. She is a champion of evidence-based practice, data-driven care delivery, interdisciplinary collaboration, and quality patient care. Christina is committed to amplifying professional development, growth, and contributions of advanced practice.

When not working, she enjoys playing in the great outdoors of Colorado with her husband and two beautiful daughters.

Individuals with metabolic diseases are at high risk of developing or having MASLD



Mr DS: Management continued

Medical history	Laboratory tests	Staging tests	Management plan
 Age 58 years Sex M Race Caucasian BMI 34 kg/m ²			<ul style="list-style-type: none"> Lifestyle modification counseling, including high protein intake, low sodium, complex carbs, small frequent meals, and alcohol cessation Continue management of HTN and T2DM <ul style="list-style-type: none"> Any changes to therapy? Treatment of hypercholesterolemia <ul style="list-style-type: none"> Start Statin! Clinical research trial Future use of resmetirom?

What should follow-up look like?

HTN, hypertension; T2DM, type 2 diabetes mellitus.

cgmeducation.net
Consortium for Integrated Diabetes Device Education



Diana Isaacs

PharmD, BCPS, BCAC, CDCES,
BC-ADM, FADCES, FCCP

Endocrine Clinical
Pharmacy Specialist
Director, Education
& Training in Diabetes
Technology
Cleveland Clinic
Endocrinology &
Metabolism Institute
Cleveland, Ohio

Partnership in MASLD/MASH Management: A Multidisciplinary Approach

Case 1: Courtney

- Courtney is a 58yo F seeing me for T2D
- Meds: Insulin glargine 50 units daily, insulin aspart 10 units TID a.c., empagliflozin 10mg daily, dulaglutide 4.5mg weekly
- A1C=7.7%, TIR=54%, BMI=34kg/m²
- FIB-4 auto calculated in note

Fibrosis-4 Score	FIB-4 = (Age ³ x AST) / (Platelets in 1000/uL x (ALT))	Age 35-64
		<ul style="list-style-type: none">• <1.3 Advanced fibrosis excluded• 1.3-2.67 Further investigation needed• > 2.67 Advanced fibrosis likely
		Age ≥ 65
		<ul style="list-style-type: none">• <2.0 Advanced fibrosis excluded• 2.0-2.67 Further investigation needed• > 2.67 Advanced fibrosis likely

cgmEDUCATION.net
Consortium for Integrated Diabetes Device Education

Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP is an Endocrinology Clinical Pharmacy Specialist. She serves as the Co-Director of Endocrine Disorders in Pregnancy and the Director of Education and Training in Diabetes Technology at the Cleveland Clinic Endocrinology and Metabolism Institute. Dr Isaacs earned her bachelor's degree in chemistry from the University of Illinois at Chicago, Doctor of Pharmacy Degree from Southern Illinois University Edwardsville (SIUE) and completed a pharmacy practice

residency at the Philadelphia Veterans Affairs. Dr Isaacs holds board certifications in pharmacotherapy, ambulatory care, and advanced diabetes management. She served on the American Diabetes Association (ADA) Professional Practice Committee from 2020-2023, the committee that updates the ADA Standards of Care.

She is a National Board Member of the Association of Diabetes Care and Education Specialists (ADCES). She co-hosts a podcast titled "Diabetes Dialogue: Technology, Therapeutics and Real-World Perspectives". She was the ADCES Diabetes Care and Education Specialist of the Year in 2020 and inducted into the SIUE Hall of Fame in 2022 for her far reaching contributions in diabetes care.

Fibroscan Results & Referral

- Fibroscan Results
 - IQR %: 17%
 - E (kpa): 21.2
 - CAP: 356
- Referral to MASLD Multidisciplinary Clinic for definitive fibrosis staging
- Visit with endocrinologist focused on weight management/metabolic disease risk
- Visit with hepatologist

cgmEDUCATION.net
Consortium for Integrated Diabetes Device Education

Assessing MASLD/MASH Risk

FIB-4 Calculation: 2.31

Calculated from:


SGOT/AST: 42 U/L

SGPT/ALT: 34 U/L

Platelets: 159 k/uL

• Age: 51 years

• Fibroscan ordered



Diabetes Care 2025;48(Suppl. 1):S59-S85

cgmEDUCATION.net
Consortium for Integrated Diabetes Device Education

>40,000 Members *and growing*

Multi-Award Winning
Medical Education



Membership (Free) Benefits



- Email updates on latest CME programs/webcasts
- Early/Pre-registration for online and live meetings and programs
- Access to SpeakerReady slide lecture guide
- One-time log-in for all “members-only” site activities (optional)

Go to cgmEDUCATION.net/member

**Become a
Member
Now!**



Refer-a-Colleague

Would a colleague be interested in cgmEDUCATION.net?

Go to cgmEDUCATION.net/refer

**Refer a
Colleague
Now!**

Partner with Us!

Design · Production · Promotional support

Listed on Resources page

Exposure to >40,000 Members (Diabetes Specialists) *and growing!*



info@cgmEDUCATION.net



This activity is supported by an independent educational grant provided by **Madrigal Pharmaceuticals.**